The US pharmaceutical company Modena revealed that the results of a phase 3 clinical trial on its vaccine showed 94.1% of the effect similar to the preliminary analysis.
In particular, Modena explained that its vaccine was 100% effective in preventing severe symptoms of COVID-19, and that no serious safety issues were found.
Modena plans to immediately apply for emergency use authorization to US and European authorities.
It is known that the Korean government plans to secure modders or vaccines through COVAX, an international vaccine partnership.